A dult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. It is the second most common type of acute leukemia in adults. AML is also sometimes referred to as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, and acute nonlymphocytic leukemia.
aml classification
Genetic mutations, often in genes coding for signaling proteins or transcription factors, are required to promote the transformation to LSCs and, consequently, overt AML. 3 Genetic alterations in the tumor cell have been recognized as a cause of leukemia, initially described as karyotypic abnormalities (eg, deletions, translocations) that are detectable by cytogenetic analysis in approximately 50% of patients. 4 In addition to age and performance status, cytogenetic and molecular aberrations are the most important tools to predict outcome in AML. 4 The cytogenetic profile (karyotype or chromosomal aberrations) serves as a prognostic indicator in AML by which patients are stratified into favorable, intermediate, and adverse risk groups (Table 1) . 2, 5 Chromosome alterations and complex karyotype (described as > 3 chromosomal abnormalities) are associated with poor response to therapy and reduced survival. The presence of other cytogenetic abnormalities, such as t(8;21) or inv (16) in core-binding factor AML indicate longer disease remission and survival. Approximately 40% to 50% of all AML cases are cytogenetically normal AML (CN-AML). CN-AMLs have an intermediate risk for relapse. With respect to clinical outcomes, substantial heterogeneity is observed in this group. 4 AML is characterized by multiple somatically acquired mutations that affect genes of different functional categories (Box 1). Mutations in genes encoding epigenetic modifiers, such as DNMT3A, ASXL1, TET2, IDH1, and IDH2, are commonly acquired early and are present in the founding clone. By contrast, mutations involving NPM1 or signaling molecules (FLT3, TP53, RAS gene family) are typically secondary events that occur later during leukemogenesis. 4, 6 With a frequency of approximately 30%, AML with NPM1 mutation represents the largest class of AML. About 75% of patients also carry mutations in DNA methylation or hydroxymethylation genes (DNMT3A, IDH1, IDH2 R140 , TET2); 40% have concurrent FLT3 internal tandem duplication (FLT3-ITD) mutations; 20% have NRAS mutations; and approximately 20% exhibit mutations in cohesion complex genes (RAD21, SMC1A, SMC3). 6 These mutations have been found to affect clinical outcomes such as remission rates, disease-free survival, event-free survival, and overall survival (OS). 7 Other disease characteristics of the patient (age, comorbidities, disease status, response to chemotherapy, donor availability for hematopoietic stem cell transplantation (HSCT), and patient/prescriber preference) are also considered when individualizing treatment options. 2 Two staging systems are commonly used for AML. The French-American-British (FAB) classification system 8 is based on morphology to define specific immunotypes. The World Health Organization (WHO) classification reviews chromosome translocations and evidence of dysplasia. 9 While the FAB classification system is useful and is still commonly used to group AML into subtypes, it does not take into account many of the factors that are known to affect prognosis. The WHO system is a newer system that divides the diagnosis into specific groups ( Table 2) . This classification of AML is more clinically useful and produces more meaningful prognostic information than the FAB criteria. 10 The current WHO classification is based on lineage demonstrated by cell surface antigen expression. Distinct subtypes within each lineage are further defined based on morphology, immunophenotyping, and molecular genetics. 2 New somatic/acquired gene mutations have refined the classification of myeloid neoplasms and have been in- ASXL1 mutations are also associated with resistance to chemotherapy and independently associated with shorter OS.
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CEBPA
The CCAAT enhancer binding protein alpha (CEBPA) is an intronless gene with a single exon that encodes for a transcription factor that controls gene expression during hematopoiesis. 4 Mutations in CEBPA are observed in 6% to 10% of all AML and 15% to 19% of CN-AML cases and commonly in association with del(9q). Bi-allelic mutations occurred in 4% to 5% of AML cases 4 and are associated with a normal karyotype. 6 Germline CEBPA mutations are also observed in familial AML cases.
7 FLT3-ITD co-occurs with CEBPA mutations in 22% to 33% of AML cases. 7 AML patients with bi-allelic CEBPA mutations have an increased CR rate, longer remission rates, favorable survival, and a relatively good prognosis. 4, 7 AML with a single CEBPA mutation is associated with survival rates similar to that of AML with wild-type CEBPA. 4 Patients with CN-AML who have mutated CEBPA, in the absence of FLT3 mutations, can be offered intensive chemotherapy alone, sparing the potential complications of HSCT.
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DNMT3A
Mutations in the DNA methytransferase 3A gene (DN-MT3A) have recently been identified as pre-leukemic mutations, arising early in AML evolution and persisting in times of remission. 4 They occur in 18% to 22% of all AML cases and approximately 34% of CN-AML cases. 4 They often cooccur with mutations in FLT3 (ITD or tyrosine kinase domain [TKD]), NPM1, and IDH1. 7 Patients with AML harboring DNMT3A mutations tend to have shorter OS. 7 It was reported that patients with DNMT3A-mutated AML have an inferior survival when treated with standard-dose anthracycline induction therapy. High-dose daunorubicin compared with standard-dose daunorubicin improved the rate of survival among patients with DNMT3A or NPM1 mutations or KMT2A translocations, but not among patients with wildtype DNMT3A, NPM1, and KMT2A.
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FLT3
FLT3 encodes a class II family receptor tyrosine kinase that acts as a cytokine receptor for the FLT3 ligand 4 and is responsible for the proliferation and differentiation of hematopoietic stem cells. 7 In normal bone marrow, FLT3 is expressed only on immature hematopoietic stem cells. FLT3 mutations are among the most frequent mutations observed in AML, occurring at a frequency of 20% to 30%, and 2 types are distinguished: FLT3-ITD (75%-80%) and FLT3-TKD (20%-35%). 4, 7 Both types of mutations constitutively activate FLT3 signaling, promoting blast proliferation. 4 The FLT3-ITD mutation has a negative prognostic effect in AML. Normal-karyotype AML patients bearing an FLT3-ITD mutation have a poorer prognosis than AML patients with wild-type FLT3. 7 TKD predict a particularly poor prognosis. FLT3-ITD mutations are associated with increased risk of relapse. In AML with an FLT3-ITD mutation, the high relapse rate and poor outcome depend mainly on the ITD allelic ratio. 4 This effect on prognosis is modulated by the mutated to wild-type allele ratio, with inferior outcome in the presence of an increased load of ITDs in FLT3.
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IDH1/2
Mutations of the isocitrate dehydrogenase (IDH) 1 and 2 genes are gain-of-function mutations. These mutations lead to novel enzymatic activity leading to the production of a putative oncometabolite, inhibiting TET2 function, increasing global DNA hypermethylation, and impairing hematopoietic cell differentiation.
7 IDH1 and IDH2 mutations were discovered in 15% to 25% AML. 7 They are found more frequently in older patients and also in non-hematological tumors. 4 IDH1 and IDH2 mutations are frequently associated with normal karyotype AML (25%-30%) and NPM1 mutation. 7 IDH mutations are associated with reduced survival in CN-AML cases with NPM1 mutations and wild-type FLT3.
4 IDH1/2 gene mutations have been considered a potential predictive marker with hypomethylating agents such as decitabine and azacytidine. 
KIT
The KIT gene encodes a type III tyrosine kinase receptor glycoprotein that is responsible for the growth, proliferation, and differentiation of hematopoietic cells, melanocytes, and germ cells. This mutation is rare in AML (<5%) but present in 20% to 25% in AML with t(8;21) and 30% in AML with inv (16) . KIT mutations are associated with an increased risk of relapse and negate the good prognosis of core-binding factor AML. KIT mutations confer increased relapse risk and reduced survival. 4 ,7
KMT2A
The lysine methyltransferase 2A (KMT2A) plays roles in hematopoiesis and cell differentiation and is rearranged commonly by translocations in acute lymphoblastic leukemia and AML. In adult CN-AML, the frequency of KM-T2A rearrangement is 11%. 4 Translocations affecting the KMT2A gene and NPM1 mutations are mutually exclusive. The KMT2A partial tandem duplication (KMT2A-PTD) mutation is seen in 3% to 7% of AML and is associated with a normal karyotype (5%-11%) and trisomy 11 (90%).
KMT2A-PTD has been associated with shorter OS and a poorer prognosis compared with CN-AML without the KMT2A-PTD.
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NPM1
NPM1 encodes a nucleolar protein implicated in multiple cellular functions. Mutations in NPM1 are usually small insertions (4-11 bp in size) that result in a frameshift during translation and aberrant cytoplasmic localization of the NPM1 protein. 6 Mutations in the NPM1 are among the most common genetic changes in AML (occurring in 25%-35% of patients), especially in CN-AML (present in 45%-64%). 4 Almost 40% of NPM1-mutated AML patients have FLT3-ITD mutations. AML patients with an NPM1 mutation and FLT3 wild-type have better complete remission, event-free survival, and OS compared with patients with NPM1 and FLT3 mutations. However, patients with mutated FLT3-ITD and mutated NPM1 have better prognosis that patients with mutated FLT3-ITD and wild-type NPM1. 
RUNX1
RUNX1 is a transcription factor regulating hematopoiesis and myeloid stem cell differentiation into mature cells. Somatic mutations of RUNX1 have been identified in 5% to 20% of AML. RUNX1 mutations are associated more with older patient age, normal karyotype AML, and KMT2A and IDH mutations. RUNX1 mutations are mutually exclusive with NPM1 and CEBPA mutations but tend to co-occur with ASXL1, SRSF2, IDH2, and KMT2A-PTD. RUNX1 mutations are associated with high-risk disease and a poorer prognosis in patients with AML.
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RUNX1 mutations in AML are associated with poor outcomes, which contrast with the favorable prognostic effect of gene fusions involving RUNX1. RUNX1 mutations are associated with resistance to standard induction therapy with inferior survival for both younger and older patients. RUNX1 mutations were associated with inferior survival.
4,9
TET2
TET2 is a key regulator in hematopoietic stem cell renewal and differentiation. TET2 mutations are loss-offunction mutations and result in increased self-renewal of stem cells, myeloid hyperplasia, and impaired differentiation. TET2 mutations are seen in 7% to 25% of AML. TET2 mutations co-occur with mutations of EZH2 and IDH2 mutations and are commonly associated with a normal karyotype in AML. 4, 7 The prognosis for AML patients is not yet clear. However, patients with TET2 mutations show a greater response to azacytidine compared with those with wild-type TET2.
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TP53
TP53 is a tumor suppressor gene that plays a critical role in cell cycle regulation, DNA repair, and apoptosis. P53 protein binds directly to DNA and determines whether the cell undergoes repair, senescence, or apoptosis in response to cellular stress or damage. Missense mutations are quite common (70%-80%), resulting in impaired function and facilitating the evolution of malignant neoplasms. TP53 mutations are present in 5% to 18% of de novo AML. In cases of AML with a complex karyotype, the frequency of TP53 mutation is 50%. 4 In general, TP53 mutations confer an adverse prognosis with documented chemoresistance. TP53 mutations may be mainly responsible for the very poor prognosis of complex karyotype AML. 4 TP53 mutations are independently associated with shorter OS and resistance to chemotherapy, hypomethylating agents, and stem cell transplantation in patients with myelodysplastic and AML. 6 Patients in the subgroup AML with TP53 mutations, chromosomal aneuploidy, or both, are significantly older and more frequently have secondary AML and poor outcomes. current paradigm for aml diagnosis and treatment AML usually progresses very quickly if it is not treated. Treatment of AML should be sufficiently aggressive to achieve a complete remission (CR), because partial remission offers no substantial survival benefit.
Current treatment for AML involves 2 phases. The first, induction therapy, is an intensive chemotherapeutic regimen that attempts to eradicate the leukemia and normalize blood counts. Treatment with 7 days of cytarabine and 3 days of an anthracycline ("7 + 3" regimen) remains the current standard for remission-induction therapy. For patients with FLT3-mutated AML, midostaurin, an inhibitor of FLT3-ITD and FLT3-TKD mutations, may be added to the chemotherapy regimen. 11 Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 IgG3 antibody conjugated to the cytotoxin calicheamicin.
12 CD33 is a transmembrane glycoprotein frequently expressed on adult and childhood AML blasts (85%-90% of patients presenting with AML). GO binds to the surface CD33, and the complex is internalized. 1 Patients shown to have high CD33 expression may be given GO as part of the induction regimen. 11 The presence of greater than 5% of leukemic blasts necessitates reinduction therapy. 2 The goals of treatment are to eradicate the disease as quickly as possible and induce complete remission, often at the cost of other aspects of the patient's health. The traditional chemotherapeutic regimen is associated with a number of side effects that range from unpleasant to life threatening, including alopecia (hair loss), mucositis (sores in the mouth and intestines), organ damage, and myelosuppression, which may lead to deadly infections. 13 Advances in the treatment of AML have resulted in substantially improved CR rates. Approximately 60% to 70% of adults with AML can be expected to attain CR status following appropriate induction therapy, depending on patient age and the presence or absence of specific somatically acquired genetic alterations. 2 Remission rates in adult AML are inversely related to age, with an expected remission rate of more than 65% for those younger than 60 years.
The second phase of treatment, post-remission therapy or consolidation, involves chemotherapy, possibly allogenic HSCT (alloHSCT), or both. Midostaurin or GO may be used as adjuvant therapy for appropriate patients. 11 Despite the use of intensive chemotherapy and HSCT, a high proportion of patients who achieve CR eventually relapse. Half of young patients (age younger than 60 years) and 80% of patients older than 60 years experience treatment failures, relapses, or treatment-related complications. 2 Even though second and even third remissions may be achieved, these are of progressively shorter duration, and cure is rarely accomplished. Together with post-remission therapy (additional chemotherapy and/or HSCT), 5-year survival rates or < 5% to 20% and > 40% are achieved for patients older and younger than 60 years, respectively. 3 An estimated 10,590 deaths (6110 men and boys and 4480 women and girls) from AML will occur this year. More 14 Improvements in therapeutic regimens and supportive care (including infection control and transfusion support) have led to improved survival for AML. However, relapse, and the associated resistance to currently available therapies, represents one of the central problems in the treatment of AML.
economic impact of aml
There are few published articles that have examined the cost burden of AML specifically. One study published in 2010 set the cost of induction therapy at $63,000. 15 In another study, health care costs and utilization during the first year after a diagnosis of AML for privately insured non-Medicare patients in the United States aged 50 to 64 years who were treated with either chemotherapy or chemotherapy and alloHCT were estimated based on MarketScan (Truven Health Analytics) adjudicated total payments for inpatient, outpatient, and prescription drug claims from 2007 to 2011. Adjusted mean 1-year costs were $280,788 for chemotherapy and $544,178 for alloHCT. 16 In a more recent study, AML patients were identified in MarketScan claims databases between 1 January 2009 and 31 January 2015. Mean (SD) health care expenditures for patients from first-line induction to remission (n = 681) were $208,857 ($152,090). Of the patients who had a second remission (n = 70, expenditures from relapse to remission were $142,569 ($208,307). 17 Given the need to hospitalize the patient upon diagnosis, the driver of costs would be related to hospital-based costs and physician payments. Once induction therapy is complete, the costs then shift to outpatient costs for drugs and laboratory as we see with many other cancers. Like many other cancers there are indirect costs and burdens; some of which can be considerable.
defining value in aml care
In addition to the run up in costs, and the pressures of newly-approved drugs and others in the pipeline that are expected to come to market, the existing drugs will gain new indications and will be prescribed more frequently. Treatment cycles will extend beyond current recommendations. Many drugs will also be used in post-acute treatment maintenance. There is also the issue of off-label or outside-of-approval use of therapies. An important question to ask is: Where is the evidence of success? How do we evaluate and determine the value of extending treatment? This creates several legal and ethical questions around balancing the appropriate use of agents with the perception (often cited by advocates) of care.
Managed care needs to appreciate the expanded indications of existing drugs and how this changes the standard of care, whether that be more frequent or longer use. Our biggest source of concern is the off-label use of biologics, determining what level of evidence is acceptable in order to allow this use, and what issues, if any, are created by this use. As treatments evolve and new lines of therapy are added, we are seeing treatments designed to maintain the patient beyond the acute phase of treatment. This is another area where organizations will need to appreciate the value of these therapies.
I think we can all agree that the treatment of cancer is very complex and expensive. Managed care organizations struggle to find the right benefit design that allows the patient to access the care that they need at a price that is affordable to both the patient and society. The Institute of Medicine (now part of the National Academy of Medicine) has described quality medical care as patient-centered, safe, timely, equitable, effective, efficient, and sustainable. 18 To me, "efficient and sustainable" means that cost is central to quality. Cost is also central to achieving an equitable distribution of health care with timely access. Organizations attempt to provide this by balancing and developing coverage and benefit language that enables access while controlling utilization and managing costs in order to ensure the organizations survival. Challenges are plentiful, and companies have well-defined mechanisms for decision-making and implementation. Organizations are always looking for new and more efficient models of care not only to control costs by also to improve quality.
In addition, patients should not be excluded from this discussion. What patients really want is to build a partnership with their treatment team. They want access to quality care with compassion and respect. While all of these domains are very important, what is most important is that patients and their families want hope. Partnering requires that clinicians actively interact with patients, provide them with the necessary medical information to make an informed decision and engage the patient in both the conversation and decision making. In short, a working partnership of patient and clinician provides the foundation for patient engagement and empowers the patient to be the steward of their own health care.
Is there a place here for a collaborative practice such as the medical home? While many of the services are similar to what oncology practices currently offer could an organized medical team with highly defined responsibilities and workflows provide efficient, patient-centered care that improves outcomes, lowers treatment costs, and provides an enhanced patient experience?
Although the concept of the medical home has been around since the 1960s, it has in the past decade been adopted in many primary care settings. In oncology, the care would be directed by the patient's oncologist who would lead the team depicted here, who collectively take responsibility for the care of the patient. Each team member would apply his or her expertise toward improving the overall health status of the patient. The major challenge to this approach is in setting the correct reimbursement levels to support this type of practice.
